Related Experiment Videos

Molecular pathways: targeting p21-activated kinase 1 signaling in cancer--opportunities, challenges, and limitations

Jeyanthy Eswaran1, Da-Qiang Li, Anil Shah

  • 1McCormick Genomic and Proteomics Center, George Washington University, Washington, DC, USA.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|May 19, 2012
PubMed

Insights

p21-activated kinase 1 (PAK1) is crucial in cancer cell evolution and progression. Targeting PAK1 offers a promising strategy for novel anticancer therapies and prognostic markers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Cancer cell evolution involves deregulation of fundamental cellular pathways.
  • p21-activated kinase 1 (PAK1) is a key regulator implicated in various cellular functions.
  • PAK1 is frequently upregulated in human cancers, correlating with tumor progression and treatment resistance.

Purpose of the Study:

  • To summarize recent findings on PAK1 molecular pathways in human cancer.
  • To discuss the potential of PAK1 as a drug target and prognostic marker.
  • To review the current status of PAK1-targeted anticancer therapies.

Main Methods:

  • Review of recent scientific literature on PAK1 in cancer.
  • Analysis of structural and biochemical studies on PAK1 activation mechanisms.
  • Examination of emerging reports on PAK1 as a prognostic marker.

Main Results:

  • PAK1 plays diverse roles in cancer, including signaling, cytoskeleton remodeling, survival, and transcription.
  • PAK1 activation mechanisms are well-defined, enabling targeted drug development.
  • PAK1 and its phosphorylated substrates show potential as cancer prognostic markers.

Conclusions:

  • PAK1 is a significant factor in human cancer development and progression.
  • Targeting PAK1 presents a viable strategy for developing new anticancer drugs.
  • PAK1-based biomarkers may aid in cancer prognosis.

Related Concept Videos

Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...